clinical trial · NCT07621471
IL-15 Enhanced NK Cell Therapy for Solid Tumors
Genovn Therapeutics (Suzhou) Co., Ltd.·early phase1·not yet recruiting·n = 12
Solid TumorsMetastatic CancerIL-15 enhanced engineered NK cellsIL-15 Enhanced Engineered NK Cells
brief summary
A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.
started
Jul 1, 2026
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Jun 2, 2026
official title
A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed/Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol